About this trial
The aim of this randomized controlled trial is to further examine the possible effects of low dose human chorionic gonadotropin (hCG) priming for eight weeks in women with diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The investigators want to retest the findings of our first study in an identical paired design (NCT04643925), as an increase of 1.5 in mean number of oocytes retrieved is clinically relevant. To incorporate the strengths of a randomized controlled trial design, women will be randomized after their first ICSI treatment to receive either hCG or placebo in a double-blinded design during an eight-week priming period preceding their second ICSI treatment. The primary outcome is the number of oocytes retrieved in the second ICSI treatment.
Eligibility criteria
Qualifiers
Age 18-40 (both inclusive)
Regular menstrual cycle (23-35 days)
1.-5. IVF/ICSI cycle at inclusion
AMH < 6.29 pmol/L (Elecsys® AMH assay)
Disqualifiers
Uterine malformations or hydrosalpinx
Submucosal uterine myomas
Uterine polyps
Allergy to standard IVF/ICSI medication
Trial design
Treatments tested in this trial
- Choriongonadotropin alfa (hCG)
- Isotonic NaCl (Placebo)
Treatment groups
Sponsors and collaborators
Kristine Loessl
Lead sponsor
Rigshospitalet, Denmark
Sponsor institution
Copenhagen University Hospital, Hvidovre
Collaborator
Copenhagen University Hospital at Herlev
Collaborator
Odense University Hospital
Collaborator